Emerging-market health care growth is expected to increase at three times the rate of developed markets.

Emerging markets, including Russia,
India and China, will help drive 70 percent
of the pharmaceutical industry growth in
the next five years.

Established Products Division

Abbott’s new Established Products Division expands our growing branded generics portfolio outside the United States, primarily in emerging markets. Branded generic products have a strong brand identity, patient trust and a reputation for quality.

Abbott’s international sales have more than quadrupled over the last 10 years as we continue to expand into new geographies.

The acquisitions of Solvay Pharmaceuticals and Piramal Healthcare Solutions added hundreds of products and made Abbott the number-one pharmaceutical company in India.